Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:
1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.
Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.
Based on those aspects listed above, GuruFocus believes the risk assessment of Oncotelic Therapeutics is: No Data: Cannot be evaluated.
Competitive Comparison of Oncotelic Therapeutics's Risk Assessment
For the Biotechnology subindustry, Oncotelic Therapeutics's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oncotelic Therapeutics's Risk Assessment Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Oncotelic Therapeutics's Risk Assessment distribution charts can be found below:
* The bar in red indicates where Oncotelic Therapeutics's Risk Assessment falls into.
(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.
Oncotelic Therapeutics Risk Assessment Related Terms
Thank you for viewing the detailed overview of Oncotelic Therapeutics's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.
Oncotelic Therapeutics (Oncotelic Therapeutics) Business Description
Oncotelic Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing drugs for the treatment of orphan oncology indications, developing antisense and small molecule injectable drugs for the treatment of cancer with a focus on rare pediatric cancers, and addressing the current global pandemic. OT-101 is its lead immuno-oncology drug candidate. OT-101 also has activity against SARS-CoV-2. Its other products under pipeline are Artemisinin, CA4P, and Oxi4503. Currently, the company generates revenues from rendering services to other third-party customers for the development of certain drug products or in connection with certain out-licensing agreements.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
OTLC has been successfully added to your